I am honored to have been chosen as the new Editor-in-Chief of Tumor Biology. Much has changed since the Journal was launched in 1980. Initially known under the name of Oncodevelopmental Biology and Medicine, it is the official journal of The International Society of Oncology and Biomarkers (ISOBM), founded by scientists researching the proteins involved in embryonic development as tumor markers. These included Dr. Gary Abelev, who discovered alpha-fetoprotein (AFP) and Dr. Phil Gold, who discovered carcinoembryonic antigen (CEA). Over the years, following major developments in experimental and clinical cancer research, the scope of the journal has broadened, and Tumor Biology had become one of the largest (in terms of the number of publications) in the field of tumor biology.
I would like to acknowledge the support and cooperation of our new publisher. When SAGE Publishing took over in January 2017 Tumor Biology became fully open access, so that the articles are now readily available to the research community.
We also have a distinguished Editorial Board, including internationally recognized opinion leaders.
I would also like to express my gratitude to my predecessor, Professor Torgny Stigbrand, who has been fully committed to the journal for 17 years and significantly developed the journal.
My vision for Tumor Biology is to maintain and enhance its important position as a cancer research journal, publishing high-quality articles, significant and interesting for tumor biology scientists, diagnosticians and oncologists worldwide. To achieve this objective, I will continue to focus on tumor markers/molecular biomarkers, mechanisms of tumor development and progression, and tumor targeting. I will also welcome translational cancer research studies, hot-topic reviews, and inspiring commentaries, including controversies, current research trends and future developments in the field. I will also welcome guidelines for the use of tumor markers. Special issues around significant, high-profile topics and conference proceedings will also be published.
Tumor Biology, while aiming for rapid publishing decisions, runs a rigorous review process, and gives particular attention to ethical issues such as plagiarism, self-plagiarism and conflicts of interest. All papers are reviewed by independent reviewers only, to provide accurate evaluations.
I would like to encourage all prospective authors to submit manuscripts to Tumor Biology.
The Editorial Board, SAGE Publishing and the authors are working together on developing the journal for the benefit of the research community.
Adapted from Chechlinska, M. (2018). Tumor Biology: A new chapter. Tumor Biology. https://doi.org/10.1177/1010428317748815